Floatz logo

CD47/SIRPA-BLOCKING AGENT ALX148

Progesterone-Receptor Positive Breast Cancer

QuantumLeap Healthcare Collaborativeprotein_peptidePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Progesterone-Receptor Positive Breast Cancer cohort.

Asset / SponsorPhaseRating
Tamoxifen
Jennifer Lee Caswell-Jin
Phase 2BB
Letrozole
Ruth O'Regan
Phase 2BB
Nivestim
University of Washington
Phase 2B
Cyclophosphamide
University of Washington
Phase 2B
Melphalan
Fred Hutchinson Cancer Center
Phase 2B

View all 36 →

Same molecule, other indications

CD47/SIRPA-BLOCKING AGENT ALX148 is also rated in:

breast cancerActive
B
Indicative · Phase 2
60 / 100
View asset →
plasma cell myelomaActive
CCC
Indicative · Phase 1/2
48 / 100
View asset →
composite lymphomaActive
CCC
Indicative · Phase 1/2
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →